PRQR logo

PRQR
ProQR Therapeutics N.V

4,352
Mkt Cap
$194.92M
Volume
430,193.00
52W High
$3.10
52W Low
$1.08
PE Ratio
-4.07
PRQR Fundamentals
Price
$1.85
Prev Close
$1.98
Open
$2.02
50D MA
$1.61
Beta
1.03
Avg. Volume
393,745.75
EPS (Annual)
-$0.452
P/B
3.29
$120.67
Loading...
Loading...
News
all
press releases
ProQR Therapeutics (NASDAQ:PRQR) Earns "Buy" Rating from Chardan Capital
Chardan Capital reiterated a "buy" rating and issued a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Aberdeen Group plc Has $5.96 Million Holdings in ProQR Therapeutics N.V. $PRQR
Aberdeen Group plc increased its holdings in ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) by 28.4% during the fourth quarter, according to its most recent 13F filing with the Securities and...
MarketBeat·2d ago
News Placeholder
ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This Quarter
ProQR Therapeutics (NASDAQ:PRQR) outlined multiple pipeline updates and development priorities during its virtual investor and analyst event, highlighting upcoming clinical readouts for its lead RNA...
MarketBeat·3d ago
News Placeholder
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Recommendation of "Moderate Buy" by Brokerages
ProQR Therapeutics N.V. (NASDAQ:PRQR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight analysts that are covering the stock, MarketBeat reports. One analyst...
MarketBeat·10d ago
News Placeholder
Q2 Earnings Estimate for PRQR Issued By HC Wainwright
ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) - Research analysts at HC Wainwright issued their Q2 2026 EPS estimates for shares of ProQR Therapeutics in a report released on Monday, March...
MarketBeat·24d ago
News Placeholder
Brokers Issue Forecasts for PRQR Q1 Earnings
ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of ProQR Therapeutics in a note issued to...
MarketBeat·25d ago
News Placeholder
ProQR Therapeutics (NASDAQ:PRQR) Raised to Hold at Wall Street Zen
Wall Street Zen raised shares of ProQR Therapeutics from a "strong sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·28d ago
News Placeholder
ProQR Therapeutics (NASDAQ:PRQR) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS
ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.09) EPS for the quarter, missing the consensus...
MarketBeat·29d ago
News Placeholder
ProQR Therapeutics (NASDAQ:PRQR) Coverage Initiated at Oppenheimer
Oppenheimer started coverage on ProQR Therapeutics in a report on Thursday. They set an "outperform" rating and a $9.00 price objective on the stock...
MarketBeat·1mo ago
News Placeholder
ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates
ProQR (PRQR) delivered earnings and revenue surprises of -12.50% and -36.14%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
<
1
2
...
>

Latest PRQR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.